BridgeBio Pharma Inc is a pioneering biopharmaceutical company focused on developing innovative medicines for genetic diseases and cancers. With a robust pipeline, it is advancing treatments through clinical trials, including therapies for TTR amyloidosis, achondroplasia, congenital adrenal hyperplasia, autosomal dominant hypocalcemia, and limb-girdle muscular dystrophy. Founded in 2015 and based in Palo Alto, California, BridgeBio collaborates with leading institutions to transform scientific discoveries into breakthrough treatments.